Marcaine 0,5% Adréenaline

Bupivacaine hydrochloride, the active ingredient in Marcaine 0,5% Adréenaline, is a long‑acting local anesthetic presented as a 0.5% (w/v) injectable solution combined with epinephrine for epidural and infiltration use. It provides profound, site‑specific anesthesia for surgical procedures and other invasive interventions.

GNH USA supplies Marcaine 0,5% Adréenaline as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product conforms to EU pharmacopeial specifications and is manufactured under GMP conditions. It is distributed through a validated cold‑chain logistics network to maintain stability.

Marcaine 0,5% Adréenaline, a local anesthetic used in regional anesthesia, is indicated for the following clinical situations: - Local anesthesia for surgical procedures: Provides site‑specific numbness to facilitate operative interventions. - Epidural anesthesia: Produces sensory and motor block for obstetric, orthopedic or abdominal surgeries. - Infiltration anesthesia: Delivers targeted analgesia for minor procedures and postoperative pain control.

Marcaine 0,5% Adréenaline may cause a range of adverse reactions.

Common Side Effects: - Injection site pain or burning sensation. - Transient hypotension or mild dizziness. - Nausea or vomiting. - Temporary metallic taste. - Mild tremor or shivering.

Serious or Rare Side Effects: - Cardiovascular toxicity such as arrhythmias or severe hypertension. - Central nervous system toxicity including seizures or loss of consciousness. - Severe allergic reactions or anaphylaxis. - Prolonged motor block or neuropathy. - Methemoglobinemia (rare).

When using Marcaine 0,5% Adréenaline, consider the following precautions: - Pregnancy: Safety not established; use only if benefit outweighs risk. - Cardiovascular disease: Monitor for arrhythmias and blood pressure changes due to epinephrine. - Dosage adjustment: Administer only by qualified professionals; adjust for age, weight, and comorbidities. - Allergy: Avoid in patients with known hypersensitivity to bupivacaine or epinephrine. - Drug interactions: Review concomitant medications, especially MAO inhibitors and beta‑blockers. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Marcaine 0,5% Adréenaline can interact with several drug classes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors: May potentiate epinephrine‑induced hypertension. - Non‑selective alpha‑blockers: Can diminish vasoconstrictive effect, increasing systemic bupivacaine exposure. - Other local anesthetics: Concurrent use raises risk of systemic toxicity.

Moderate Interactions (Monitor Closely): - Beta‑blockers: May mask tachycardia caused by epinephrine. - Calcium channel blockers: Potential additive cardiovascular effects. - Diuretics: May alter plasma concentration of bupivacaine.